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Abstract: The 3,3′,5,5′-tetrachloro-2-iodo-4,4′-bipyridine structure is proposed as a novel chemical
scaffold for the design of new transthyretin (TTR) fibrillogenesis inhibitors. In the frame
of a proof-of-principle exploration, four chiral 3,3′,5,5′-tetrachloro-2-iodo-2′-substituted-4,4′-
bipyridines were rationally designed and prepared from a simple trihalopyridine in three steps,
including a Cu-catalysed Finkelstein reaction to introduce iodine atoms on the heteroaromatic
scaffold, and a Pd-catalysed coupling reaction to install the 2′-substituent. The corresponding
racemates, along with other five chiral 4,4′-bipyridines containing halogens as substituents, were
enantioseparated by high-performance liquid chromatography in order to obtain pure enantiomer
pairs. All stereoisomers were tested against the amyloid fibril formation (FF) of wild type (WT)-TTR
and two mutant variants, V30M and Y78F, in acid mediated aggregation experiments. Among
the 4,4′-bipyridine derivatives, interesting inhibition activity was obtained for both enantiomers of
the 3,3′,5,5′-tetrachloro-2′-(4-hydroxyphenyl)-2-iodo-4,4′-bipyridine. In silico docking studies were
carried out in order to explore possible binding modes of the 4,4′-bipyridine derivatives into the TTR.
The gained results point out the importance of the right combination of H-bond sites and the presence
of iodine as halogen-bond donor. Both experimental and theoretical evidences pave the way for the
utilization of the iodinated 4,4′-bipyridine core as template to design new promising inhibitors of
TTR amyloidogenesis.
Keywords: bipyridines; docking; fibril formation; halogen bond; misfolding inhibition; transthyretin
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1. Introduction
Human transthyretin (hTTR, prealbumin) is a homotetrameric protein (55 kDa) made up of four
subunits (A-B-C-D, Figure 1a), each composed of 127 aminoacids [1–3]. The protein is mainly produced
by the liver, but other sources of TTR, including the choroid plexus, the retinal pigment epithelium,
and the α-cells of pancreatic islets are known. TTR is involved in the transport of thyroid hormones
(thyroxine (T4) and triiodothyronine (T3)) (Figure 1b) in blood and cerebrospinal fluid. The tetrameric
assembly of TTR contains a central hydrophobic channel with two symmetrical funnel-shaped T4
binding pockets located at the energetically weaker dimer-dimer A-B/C-D interface [4], the other
A-C/B-D interface being stabilized by interstrand hydrogen bonds (HBs).
Figure 1. (a) Ribbon diagram picture of wild type (WT)-TTR (released from PDB ID 1ICT [2]);
(b) structures of thyroxine (T4), triiodothyronine (T3), tafamidis and other ATTR drug candidates under
clinical trials.
The presence of mutations in TTR results in destabilization of the tetramer and dissociation
into amyloidogenic monomers, which misfold and self-aggregate into insoluble amyloid fibrils.
TTR amyloidogenesis has been implicated to cause amyloid diseases (TTR amyloidosis, ATTR) [5,6].
Amyloid structures derived from wild-type (WT)-TTR can deposit in the heart and peripheral nerves
causing senile systemic amyloidosis (SSA), whereas over 100 TTR mutants were shown to be implicated
in three other groups of diseases, namely familial amyloidotic polyneuropathy (FAP), cardiomyopathy
(FAC), and central nervous system selective amyloidosis (CNSA). Among known TTR mutants,
the V30M [7] and the Y78F [8] are the most common FAP mutation and the most amyloidogenic,
respectively. Moreover, the importance of TTR stability also concerns neurodegenerative disorders
such as Parkinson’s and Alzheimer’s diseases [9,10].
In 1996 it was observed that T4 is able to prevent amyloid fibril formation (FF), but with adverse
side effects due to its hormonal activity [11]. However, this study proved that stabilization of the native
TTR tetramer by small molecule binding to one or both of the T4 binding pockets could be a rationale
for the kinetic inhibition of TTR amyloidogenesis, tetramer dissociation being the rate-determining step
in amyloid formation [12,13]. Indeed, TTR can bind molecules other than T4 because more than 99% of
T4 binding sites are unoccupied due to the fact that two other carriers, albumin and thyroid-binding
globulin, transport the majority of T4 in the blood. Significantly, this observation paved the way for
the development of an oral therapy as a valid alternative to more invasive approaches [14].
In the last decades, several small molecules have proven to be able to bridge neighbouring
monomers of TTR via specific hydrophobic and electrostatic noncovalent interactions, to stabilize the
Molecules 2020, 25, 2213 3 of 21
tetramer, to inhibit the tetramer dissociation, and to reduce FF [3,15–28]. However, to date few structures
possess the requirements to be drug candidates (Figure 1b), and the ATTR still lacks an effective therapy.
So far, tafamidis [29] has been approved for clinical use in Europe and Japan for the treatment of
early-stage FAP [30], but advanced disease responds poorly to tafamidis administration [31]. Then,
recently the drug tolcapone, which was approved for the treatment of Parkinson’s disease, has been
repurposed for the treatment of ATTR [32]. Nonsteroidal anti-inflammatory drugs (NSAIDs) also
inhibit formation of amyloidogenic monomers. Among them, diflunisal was shown to slow the
progression of FAP over a period of 2 years, but adverse gastrointestinal effects limit its use [16,33].
In this regard, it is worth mentioning that small molecules should be selective for TTR and neither bind
thyroid hormone receptors nor cyclooxygenase-1 (COX-1) to be effective clinical candidates [16,18].
Over time, a large number of SAR studies have been published in order to identify typical
substructures which are shared by compounds that stabilize TTR tetramer [3,34–39]. In this
field, the potential of iodine as substituent (iodination hypothesis) has been intensively explored
through evaluating the inhibition ability of iodinated compounds with respect to non-iodinated
analogues [10,11,17,36,40–43]. Among iodinated motifs, 2,4,6-triiodophenol proved to be one of the
most potent TTR fibrillogenesis inhibitor known so far [11], and iododiflunisal was shown to stabilize
TTR [17]. Nevertheless, in some cases iodination does not improve inhibition activity [17,42,44], the
effectiveness of this strategy depending on inhibitor scaffold structure and location of iodine in the
molecular framework [42]. In general, the real function of iodine in TTR binding and stabilization still
remains unclear due to the fact that halogens as substituents can contribute to protein-ligand binding
through multiple roles such as hydrophobic centres, HB acceptors and electrophilic halogen bond (XB)
donors. In particular, XBs were found to have a relevant role in the binding of halogenated ligands
with proteins [42,45], and short I···O contacts were found to underlie the selective binding of T4 to
TTR [46]. Despite the potential of iodine substituents to contribute to TTR stabilization, studies on
iodinated compounds are reported in smaller degree compared to compounds containing fluorine,
chlorine and bromine as substituents. Currently, the scarce availability of iodinated compounds has
clearly limited the study of the iodine effect on TTR misfolding inhibition, reducing the possibility to
gather conclusive information on iodine function.
In the last few years, our groups have reported the synthesis and characterization of halogenated
4,4′-bipyridines [47–50]. These molecules were shown to be efficient as XB donors in the solid state [48]
and in solution [51,52]. On this basis, starting from the chemistry and properties of 4,4′-bipyridines
1–5 [48], we describe herein the design and synthesis of iodinated 4,4′-bipyridines 6–10 and their
evaluation as TTR fibrillogenesis inhibitor (Figure 2a). Due to the atropisomeric geometry of their
halogenated heteroaromatic scaffold, compounds 1–5 and 7–10 are chiral and exhibit (M)- and
(P)-enantiomers (Figure 2b). Quantitative evaluation of the inhibition efficacy of both (M)- and
(P)-enantiomers against TTR misfolding was performed through acid-mediated in vitro assays of
WT-, V30M-, and Y78F-TTR aggregation. The relationship between chemical structures, inhibition
activity, and binding mode was explored by molecular docking and electrostatic potential isosurfaces
(VS) analysis.
In particular, this study aims at gathering information on the potential role of substructures
containing halogen σ-holes in TTR binding and stabilization. It is noteworthy that halogenated
4,4′-bipyridines derivatives have never been designed nor tested as TTR fibrillogenesis inhibitors.
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Figure 2. (a) Structures of halogenated 4,4′-bipyridines 1–10; (b) (M) and (P) absolute configurations of
the atropisomeric 4,4′-bipyridines 1–5 and 7–10.
2. Results and Discussion
2.1. Rational Design
In the majority of the TTR:small molecule crystal structures reported to date [3], the molecule is
bound to the T4 binding site, with the exception of polyphenol (−)-epigallocatechin gallate (EGCG)
which binds TTR molecular surface [19] and few other allosteric inhibitors [24,25]. Each T4 binding
pocket is composed of a small inner cavity (delimited by the pair Ser117/Se117’), and a large outer cavity
(delimited by the pair Lys15/Lys15’), with three pairs of symmetric hydrophobic depressions named
halogen binding pockets (hBPs) (Figure 3) where the iodine atoms of T4 are located.
Figure 3. Expanded schematic view of one of the two T4 binding pockets (dimer BD), where hBP1 is
located between the side chains of Lys15/15’, Leu17/17’, Thr106/106’ and Val121/121’, hBP2 between the
side chains of Leu17/17’, Ala108/108’, Ala109/109’ and Leu110/110’ and hBP3 between the side chains of
Ser117/117’, Thr119/119’, Ala108/108’ and Leu110/110’.
As reported by Kelly and co-workers [53], typical inhibitors are characterized by two aryl rings
(ArO and ArI) connected directly or through a linker. The binding ability of this kind of molecules can
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be modulated by tuning structure and substitution pattern of the three substructures, namely ArO, ArI
and linker. Scaffolds bearing halogen substituents on one ring, and a HB centre on the other ring, which
is able to interact with Lys15 ε-NH3+ group, represent the typical motif of most inhibitors reported
so far. In general, TTR can accommodate small molecules with different orientations. Indeed, in the
forward binding mode, the phenyl ring substituted with halogens prefers the inner cavity, whereas in
the reverse binding mode it is located in the outer cavity [3,15,16].
2.1.1. Conceptual Basis
As reported [3,42,46], the possibility of XB formation emerges from the crystallographic analysis of
complexes between TTR and some of the halogenated ligands reported so far. Indeed, contacts ranging
from 2.8 to 3.5 Å have been observed between halogen substituents of small molecules and Ala109,
Ser117, and Thr119 carbonyls in TTR, acting as XB acceptors. The XB is a noncovalent interaction which
originates from the anisotropic charge distribution of bound halogens, generating an area of lower
electron density, the electrophilic σ-hole, located on the elongation of the covalent bond (Figure 4a) [54].
Figure 4. (a) Schematic description of XB. On X surface, electrostatic potential (VS) > 0 (lower electron
density) and VS < 0 (higher electron density) are indicated in blue and red, respectively. Intermediate
values are in orange, yellow, and green; (b) and (c) positions of nitrogen VS,min regions (blue) and
VS,max in the structure of halogenated 4,4′-bipyridines 1–5 and 6 (hydrogen, white). VS,max colors:
halogen, coral; chlorine, green; iodine, purple.
From this perspective, the electrostatic potential (V) is a useful tool for understanding molecular
interactive capability. In particular, the calculated positive V on the isodensity surface near the halogen
σ-hole, the VS,max, is advantageously used to assess σ-hole depth which, in turn, has been found
to be related to the strengths of XB [55,56]. On this basis, the VS values on a 0.002 au molecular
isosurface of polyhalogenated 4,4′-bipyridines 1–6, bearing iodines and chlorines as substituents, were
calculated in order to localize regions of higher (negative VS,min) and lower (positive VS,max) electron
charge density, and to profile the binding capability of diverse halogenated 4,4′-bipyridyl scaffolds
as templates for the design of new TTR stabilizers (Figure 4b,c). Several key structural aspects in
halogenated 4,4′-bipyridines highlight the interest of studying this family of molecules:
(i) 4,4′-Bipyridines 1–6 consist of two linked heteroaromatic rings that accommodate six (1–5)
and five (6) (Figure 4b,c) highly oriented halogens as substituents. 4,4′-Bipyridyl derivatives
have been almost unexplored in the field of TTR stabilization to date, and only the
5-cyano-2-methyl-3,4’-bipyridin-6(1H)-one milrinone was found to be a strong competitive
inhibitor of T4 binding to TTR [57];
(ii) The two electron-poor bipyridyl rings are characterized by positive VS,max ranging from 72.06 to
96.58 kJ/mol (Supplementary Materials, Table S1), similar to the values calculated for tafamidis,
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which contains an electron-poor substructure centred on the oxazole ring (98.49; 98.88 kJ/mol)
(Table S2);
(iii) The presence of four 3,3′,5,5′-substituents induces chirality by restricted rotation around the
4,4′-bond (atropisomerism), introducing stereochemical features that could be fruitfully exploited
to improve binding efficacy and selectivity toward TTR. So far, few studies considered chiral
inhibitors and their stereochemical properties [35]. Moreover, the atropisomeric structure of the
3,3′,5,5′-tetrasubstituted-4,4′-bipyridyl ring mimics the skewed conformation of T4;
(iv) The two pyridyl nitrogens can work as HB acceptors, exhibiting VS,min values ranging from
−122.43 to −117.07 kJ/mol (Supplementary Materials, Table S1). Furthermore, nitrogen is known
to be a high-impact design element because substitution of a CH group with a N atom, in aromatic
and heteroaromatic ring frameworks, often improves the pharmacological profile of a molecular
structure at different levels [58];
(v) Iodine is considered a powerful XB donor due to its polarizability, in particular when it is
bound to electron-withdrawing groups (EWGs). T4 presents multiple iodine atoms which are
accommodated in the hBPs of the T4 binding site of TTR. For T4, we calculated VS,max ranging
from 109.11 to 143.05 kJ/mol (Supplementary Materials, Table S2). In compounds 1 and 3–6, iodine
substituents are activated as XB donors due to the EWG effect exerted by the tetrachlorinated
heteroaromatic scaffold, with VS,max values ranging from 133.42 to 167.06 kJ/mol (Table S1). In this
regard, it is worth mentioning that in our previous studies [48–52,59], the function of compounds
1–5 as XB donors was demonstrated by theoretical calculations, and HPLC, NMR, and X-ray
diffraction (XRD) analysis involving oxygen and nitrogen as XB acceptors. On the other hand,
iodine is able to fill the hBPs better than other halogens due to its volume, so optimizing the
strength of van der Waals interactions [42];
(vi) In compounds 2–6, the chlorine substituents could also function as potential XB donors, even if
lower VS,max values ranging from 70.96 to 98.81 kJ/mol were calculated (Supplementary Materials,
Table S1) due to the lower polarizability and the higher electronegativity of chlorine with respect
to iodine. Moreover, COX-1 being characterized by smaller hydrophobic binding pockets with
respect to TTR [34,35], the presence of bulkier chlorines, with respect to hydrogens, might reduce
binding affinity of the small molecule towards COX-1, thus increasing selectivity in TTR binding;
(vii) Since compounds 3–5 contain the same type and number of halogenated substituents but a
different substitution pattern, it is possible to evaluate the scaffold effect on iodine properties
and activity. Recently, Boeckler and co-workers demonstrated by theoretical calculations that the
attachment position of a halogen within a heteroaromatic scaffold can influence size and shape of
the σ-hole and, in turn, the strength of the XB [56];
(viii) All halogens can also act as hydrophobic sites and HB acceptors due to a belt of higher electron
density located around the σ-hole (Figure 4a).
2.1.2. Molecular Docking of Polyhalogenated 4,4′-Bipyridines 1–6 in the TTR Tetramer
Molecular docking is one of the most popular computational approaches in structure-based drug
design [60]. This technique can be used either to identify the correct conformation of the ligand within
the target binding pocket or to estimate the interaction energy between a target and a ligand [61,62].
Molecular dynamics (MD) simulations can be also advantageously used to evaluate the molecular
flexibility of ligands and receptors [63]. However, as some conformational changes occur in the
time scale of only dozens of nanoseconds, this aspect could compromise the MD simulation viability
for virtual screening studies. Moreover, computational cost of MD simulations is generally high.
Therefore, a useful theoretical strategy is to select promising conformations from the docking study.
In this regard, it is worth mentioning that different programs and theoretical methods are available for
docking purposes, and each docking program shows advantages and limitations to carry out docking
studies and docking-based virtual screening [64–67]. On the other hand, Hou and co-worker recently
illustrated that no single docking program has dominative advantages than other programs [60,67].
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Herein, due to the novelty of the 4,4′-bipyridyl motif in this field, a blind docking [21] exploration was
performed in order to inspect the disposition of all enantiomers (M) and (P) of compounds 1–5 and the
achiral 6 into the whole TTR, focusing on the binding capability toward the T4 pockets. Despite the fact
that flexible docking is frequently used to model ligand-receptor complexes accounting for molecular
flexibility [64,65], we do not consider protein flexibility herein, rather focusing on the capability of
the new compounds to insert in the same T4 binding cavity hosting T4, as derived from the selected
crystal complex. For this purpose, the released crystal structure of TTR complex (PDB ID: 1ICT, chains
ABCD) [2] from the RCSB protein databank (www.rcbs.org) was used. AutoDock 4.2.6 was employed
as docking program [68,69], and the software Chimera 1.13.1 [70] for the graphical representation of the
poses derived from the docking calculation. Moreover, due to the atropisomeric features of the selected
compounds, ligand flexibility is rather limited in this case. With the aim to assess the electrophilic
behaviour of the halogens, the extra point [71,72] or explicit σ-hole (ESH) (Supplementary Materials,
Table S7) [73,74] concept was used to model the XB [51] in TTR/4,4′-bipyridine complexes. In the
context of drug design, the use of the ESH correction to model XB in drug-receptor or drug-enzyme
interactions has been recently reported [75].
For both enantiomers of 1, P-4 and M-5, all poses laid outside the T4 binding pockets, and on the
surface of only one monomer. 4,4′-Bipyridines 2, 3, 6 and the enantiomers M-4 and P-5 were found
in the T4 pockets with docking score percentages lower than 21% and binding energy ranging from
−6.14 to −4.93 kcal/mol. In particular, among all sites emerged from the blind docking procedure, the
T4 pockets were found to be the lowest energy sites for all compounds (Supplementary Materials,
Table S8). By comparing the clustering of the docking poses of the (M) series, it could be observed a
clear preference of 3 for the T4 pockets compared to compounds 4 and 5 (Figure 5a). Indeed, 21% of
docking poses of (M)-3 laid inside the T4 binding pockets, whereas lower percentages resulted for 2
and 4 (8% and 5%, respectively), these poses anchoring the side chains of the amino acid residues
which identify the three hBPs (Supplementary Materials, Table S8 and Figure S2). The lowest binding
energy values (Figure 5b) were observed for all poses of compounds 3 and 6 in the T4 pockets, thus
the 3,3′,5,5′-tetrachloro-2-iodo-4,4′-bipyridine motif showed higher binding capability for the T4
pocket with respect to the other halogenated scaffolds. With the aim to confirm the docking results,
all compounds 1–6 were tested in a first series of TTR FF assays.
Figure 5. (a) Blind docking scores for the enantiomers of compounds 1–5 and the achiral 6 in the T4
pockets; (b) docking score and binding energies of each pose of 1–6 laying in the T4 pockets.
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2.1.3. Acid-Mediated TTR FF Assay for Compounds 1–6 and Structure-Activity Relationships
Simulating the conditions found in the lysosome, the treatment of transparent solutions of
tetrameric TTR with acids induces FF and precipitation that can be observed in vitro [15]. As FF
is proportional to the turbidity degree of the parent solution, the inhibition capability of small
molecules tested as fibrillogenesis inhibitors can be derived from turbidimetry analysis [76]. On this
basis, the enantiomers of compounds 1–5 and the 2-iodinated-4,4′-bipyridine 6 were tested in this
acid-mediated TTR fibrillogenesis assay in order to evaluate their capability to inhibit FF and
precipitation. Both WT- and the mutant Y78F-TTR [8,77] were used as assay proteins. Thus,
the compounds under evaluation were first incubated for 30 min with TTR at neutral pH (36 ◦C). The
pH was then lowered to give the maximal rate of FF for a given variant (4.4 for WT, 5.0 for Y78F),
and the samples were incubated for 72 h at 36 ◦C. For each sample, the degree of FF was determined
by comparing its turbidity at 400 nm to that of a sample of TTR without test compound. On this
basis, FF percentage (FF%) characterizes compound activity. Thus, the capability of compounds 1–6 in
terms of FF% are summarized in Table 1. The assays were carried out at two inhibitor concentrations,
namely 7.2 µM (TTR/inhibitor ratio 1:2) and 3.6 µM which is equal to the TTR concentration in plasma.
diflunisal was used as the positive control, whereas TTR under acidic conditions, without inhibitor,
was fixed as a negative control (100% FF mark). On this basis, 10% FF corresponds to a compound
inhibiting 90% of TTR fibrillogenesis.
Table 1. Inhibition of WT- and Y78F-TTR amyloid fibril formation under acidic denaturation condition
in the presence of diflunisal, pure enantiomers of derivatives 1–5, and achiral 6.
Compound
FF% 1 (WT-TTR) FF% 1 (Y78F-TTR)
7.2 µM 3.6 µM 7.2 µM 3.6 µM
Diflunisal 6 18 18 43
(M)-1 99 100 100 100
(P)-1 100 100 100 100
(M)-2 93 98 89 94
(P)-2 95 97 87 93
(M)-3 94 94 72 62
(P)-3 96 100 85 87
(M)-4 96 97 87 91
(P)-4 96 99 95 95
(M)-5 90 97 85 91
(P)-5 98 98 100 94
6 91 95 73 82
1 Fibril formation (FF)% represents the extent of amyloidogenic TTR FF in the presence of inhibitors (7.2 µM or 3.6
µM inhibitor, 3.6 µM TTR, pH 4.4 (WT) or 5.0 (Y78F), 36 ◦C, 72 h), compared to untreated TTR (100% fibril formation).
The experiments were performed in triplicate and the average values are reported in the Table. The standard
deviations were in the range 5–10.
With WT-TTR, high degree of fibrillogenesis was observed for compounds 1–6 with FF% ranging
from 90 to 100%, whereas with the mutant variant Y78F slightly lower values were found in almost
all cases. In accord with the docking evaluations, in general the (M)-enantiomers were found to be
slightly more effective than the (P)-enantiomers, whereas both enantiomers of compound 1 showed no
inhibition activity against fibrillogenesis. Interestingly, compounds (M)-3 and 6 proved to be the best
inhibitors against Y78F-TTR fibrillogenesis with values ranging from 62 to 82%.
Compounds 1–6 were also docked in the T4 pocket at the BD interface in order to derive
the respective estimated free energy of binding (EFEB) (Supplementary Materials, Table S9).
The crystallographic T4 structure [2] was used as benchmark ligand to validate the docking procedure
(Supplementary Materials, Figure S3). The predictive success of the EFEB values was verified by
linear regression.
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For enantiomers 1–5 and compound 6, the results of fitting a simple linear regression model to
describe the relationship between FF% and EFEB, as an independent variable, is reported in Figure 6
for Y78F at 7.2 µM (Supplementary Materials, Figure S4 for the plots of WT-TTR and Y78F at 3.6
µM). In all cases, the P-values of the considered independent variable are lower than the statistical
benchmark value of 0.05.
Figure 6. Linear regression analysis describing the relationships between FF% (Y78F-TTR, inhibitor
concentration = 7.2 µM) and calculated EFEB by docking in the T4 pocket (BD).
It is worth mentioning that no statistical correlation was found between FF% and the EFEB values
calculated without the application of the ESH parametrization for halogens (0.1199 ≤ P-value ≤ 0.9871).
The complete inactivity of compound 1 could be related to the six bulky iodine substituents which
prevent the accommodation of the molecule in the T4 pocket. From a comparative analysis of the
structure-activity relationships, it seems that the presence of iodine substituents at positions 3,3′,5,5′
(compounds 1, 4, 5) is detrimental for both binding and inhibition activity, whereas 2- and 2′-iodine
substitutions exhibit a beneficial effect on 4,4′-bipyridine activity.
From these results, the 3,3′,5,5′-tetrachloro-2-iodo-4,4′-bipyridyl substructure (iodine VS,max
values: 140.8 kJ/mol for 3, 136.8 kJ/mol for 6) has been identified as the most interesting scaffold for
elaborating more specific compounds. On this basis, compounds 7–10 were prepared by focused
procedures to introduce a phenyl, a 4-pyridyl, a 4-hydroxyphenyl and a hydroxymethyl as a
2′-substituent, respectively. These substituents were selected to probe how subtle structural changes at
position 2′ can influence the inhibition activity.
2.2. Chemistry
2.2.1. Syntheses of 4,4′-Bipyridines 1–10
The synthesis of chiral hexahalogenated 4,4′-bipyridines 1–5 was previously reported by our
groups, exploiting convergent or divergent strategies depending on halogen type and position on the
heteroaromatic scaffold [47,48]. These methodologies proved to be extremely versatile and allowed to
introduce Cl, Br, and I at any position of the 4,4′-bipyridyl scaffold [48].
3,3′,5,5′-Tetrachloro-2,2′-diiodo-4,4′-bipyridine (3) was prepared in two steps from the commercially
available 2-bromo-3,5-dichloropyridine (11). First, a lithium diisopropylamide (LDA)-mediated
dimerization afforded 3,3′,5,5′-tetrachloro-2,2′-dibromo-4,4′-bipyridine (12), and then the bromine
atoms in 2,2′-positions were exchanged for iodines through a diaminocopper-catalyzed Finkelstein
reaction. Along with the expected 4,4′-bipyridine 3, careful chromatographic purification allowed
obtaining in small quantity the 3,3′,5,5′-tetrachloro-2-iodo- 4,4′-bipyridine 6 (Scheme 1).
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Scheme 1. Synthesis of bipyridines 6–10.
For 4,4′-bipyridines 7–9, the aromatic ring in 2-position was introduced through a Suzuki coupling
reaction involving 4,4′-bipyridine 3 and one equivalent of the respective boronic acid 13. The use of
phenyl- and 4-pyridylboronic acids 13a,b afforded 3,3′,5,5′-tetrachloro-2-iodo-2′-phenyl-4,4′-bipyridine
(7) and 3,3′,5,5′-tetrachloro-2-iodo-2′-(4- pyridyl)-4,4′-bipyridine (8), respectively.
The direct synthesis of the 3,3′,5,5′-tetrachloro-2-iodo-2′-(4-hydroxyphenyl)-4,4′-bipyridine (9)
by coupling of 3 with 4-hydroxyphenylboronic acid (13c) failed under Suzuki coupling conditions.
Therefore, compound 9 was obtained in two steps by using the tert-butyldimethylsilyl (TBS)-protected
4-hydroxyphenylboronic acid 13d. After the cross-coupling reaction between compounds 3 and 13d,
3,3′,5,5′-tetrachloro-2-iodo-2′-(4-tert-butyldimethylsilyloxyphenyl)- 4,4′-bipyridine (14) was isolated,
and the TBS-protecting group was subsequently removed by using a tetrahydrofuran solution of
tetrabutylammonium fluoride (n-Bu4NF), affording 4,4′-bipyridine 9. Finally, 3,3′,5,5′-tetrachloro-
2-iodo-2′-hydroxymethyl-4,4′-bipyridine (10) was obtained in a one-pot two-step process starting from
4,4′-bipyridine 3. After iodine-lithium exchange with one equivalent of n-butyllithium (n-BuLi) in
toluene, the lithiated species was quenched with dimethylformamide (DMF) to give the aldehyde
intermediate 15 which was directly reduced with sodium borohydride (NaBH4) to afford bipyridine 10.
2.2.2. Enantioseparation of 4,4′-Bipyridines 7–10 on Chiral Stationary Phases
Rac-4,4′-bipyridines 1–5 were enantioseparated at multimilligram scale on polysaccharide-
based chiral stationary phases, as previously reported by our groups [48,59]. Pure enantiomers
(>95% ee) of 3,3′,5,5′-tetrachloro-2-iodo-2′-substituted-4,4′-bipyridines 7–10 were obtained in good
amounts by means of HPLC multimilligram enantioseparation under normal phase elution conditions
(Supplementary Materials, Table S10). In particular, the enantiomers of compounds 7 and 9 were
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recovered by using Chiralpak IA (immobilized amylose tris(3,5-dimethyl- phenylcarbamate)) as a
chiral column, whereas the Chiralcel OD-H (cellulose tris(3,5- dimethylphenylcarbamate) was used
for the enantioseparations of compounds 8 and 10. Recorded in ethanol, the ECD spectra of the four
enantiomer pairs 7–10 showed the expected opposite traces for the two atropisomers (Supplementary
Materials, Figures S21–S24).
2.2.3. Absolute Configuration Assignment of 7–10
The absolute configuration of HPLC-separated enantiomers of bipyridines 1 and 2 was previously
assigned through XRD analysis by using the anomalous dispersion of heavy atoms [48,59]. However,
for the enantiomers of bipyridines 3–5, which could not be crystallized, the absolute configuration was
determined by electronic circular dichroism (ECD) coupled with time-dependent density functional
theory (TD-DFT) calculations [59]. Analogously, the absolute configurations assignment of enantiomers
of the newly synthesized bipyridines 7–10 was performed by comparing the measured ECD spectra
with the ones calculated by TD-DFT. The calculation of the ECD spectra was performed considering
all the possible conformers arising from the rotation of the substituent in 2′-position with respect to
the pyridine ring [78] (see Supplementary Materials, S6 for details). For each compound, except a
systematic shift of about 15 nm between the measured and calculated spectra [50,78], a very good
match was obtained allowing unambiguous absolute configuration assignment of all enantiomers
(Supplementary Materials, Table S10 and Figures S25–S28).
2.3. Biological Evaluation of Compounds 7–10 and Structure-Activity Relationships
The enantiomers of compounds 7–10 were tested by using the acid-mediated TTR FF assays
described above, in order to evaluate their capability to inhibit fibrillogenesis as soluble TTR is treated
with acidic medium. WT- and the mutants Y78F- [8], and V30M-TTR [7] were used as assay proteins,
whose stability order is WT > V30M > Y78F [7,8]. The results are reported in Table 2.
Table 2. Inhibition of WT-, Y78F-, and V30M-TTR amyloid fibril formation under acidic denaturation
condition in the presence of diflunisal, and pure enantiomers of derivatives 7–10.
Compound
FF% 1 (WT-TTR) FF% 1 (Y78F-TTR) FF%1 (V30M-TTR)
7.2 µM 3.6 µM 7.2 µM 3.6 µM 7.2 µM 3.6 µM
Diflunisal 6 18 18 43 36 33
(M)-7 96 100 82 84 nd nd
(P)-7 88 95 71 88 nd nd
(M)-8 58 72 79 82 50 58
(P)-8 42 67 51 67 38 43
(M)-9 16 49 44 71 38 40
(P)-9 17 49 44 72 39 41
(M)-10 62 79 80 88 59 75
(P)-10 80 89 85 91 67 72
1 Fibril formation (FF)% represents the extent of amyloidogenic TTR FF in the presence of inhibitors (7.2 µM or
3.6 µM inhibitor, 3.6 µM TTR, pH 4.4 (WT) or 5.0 (V30M and Y78F), 36 ◦C, 72 h), compared to untreated TTR (100%
fibril formation). The experiments were performed in triplicate and the average values are reported in the Table.
The standard deviations were in the range 5–10; nd, not determined.
Among the three TTR forms, the FF% values were higher against V30M and Y78F than WT-TTR.
On the basis of the turbidimetric assay results, the inhibition activity trend was shown to be 9 > 8
> 10 > 7, with few exceptions. Again, the (M) enantiomers were found to be more active than the
(P)-enantiomers for compounds 9 and 10, whereas the (P)-enantiomers proved to be more effective for
7 and 8. For both enantiomers of compound 9, amyloid fibrillogenesis was significantly suppressed on
WT-TTR at 7.2 µM of inhibitor concentration (FF% 16 and 17). Both (M)-9 and (P)-9 were also tested
at different concentrations ranging from 0 to 15 µM using diflunisal for comparison (Supplementary
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Information, Figure S29). As reported for other known TTR stabilizers, compound 9 dose-dependently
inhibited WT-TTR amyloidogenesis.
Structure-activity relationships revealed that a HB centre on one pyridyl ring contributes to increase
the inhibition activity, moderately for compounds 8 and 10, more for compound 9. In compound 7,
the presence of the hydrophobic phenyl, as distinctive substituent, appears to be detrimental for the
inhibition activity. Molecular docking carried out targeting the T4 pocket showed that compounds
7–10 could be accommodated in the hormone-binding site. Focusing on the four (M)-enantiomers, the
following observations emerged (Figure 7):
(i) Compound (M)-9 (Figure 7a) fully occupies the T4 pocket (molecular length 13.2 Å, VS isosurface
enclosed volume 367.0 Å3), where the 4-hydroxyphenyl group is oriented toward B:Thr106 and
B:Val121 (hBP1) and the four chlorines at the 3,3,5,5′-positions of the heteroaromatic ring anchor
the residues B:Ala108 and D:Ala108’ (hBP2). Moreover, the N’pyr (VS,min = -128.3 kJ/mol) forms a
HB with the ε-ammonium group of D:Lys15’ (2.6 Å), and 2-iodine (VS,max = 129.8 kJ/mol) showed a
short contact with the side chain oxygen of D:Ser117” (3.2 Å) (hBP3). Interestingly, the comparison
of the respective VS isosurface evidences for compound 9 a shape similarity to both T4 and
tafamidis (Supplementary Information, Figure S1);
(ii) Compound 10 (Figure 7b) is the smallest molecule of the series with a molecular length of about
9.80 Å and a volume of 303.1 Å3, therefore it is not able to fully occupy the T4 pocket, 2-iodine
showing a longer contact with B:Ser117 (4.4 Å) despite a positive VS,max value (141.6 kJ/mol).
Moreover, the best conformation of compound 10 is characterized by an intramolecular HB
involving the hydroxyl group and N’pyr (VS,min = −29.12 kJ/mol). The latter is therefore less
prone to interact with the side chain of D:Lys15’;
(iii) For both compounds 7 and 8 (Figure 7c), reverse binding modes were found by molecular
docking, with the Npyr interacting with D:Lys15’ in all cases. The basic difference between the
two compounds, which could justify the different inhibition activity, lies in the presence of a Npyr,
as a HB acceptor, at the 2′-position of compound 8 which makes possible an interaction with
B:Ser117, thus anchoring the two monomers B and D.
Figure 7. Docking modes into the T4 binding pocket (BD) for the (M)-enantiomers of 9 (a), 10 (b) and
the pair 7/8 (superimposed structures) (c).
3. Materials and Methods
3.1. Chemistry
3.1.1. General Information
Proton (1H-NMR) and carbon (13C-NMR) nuclear magnetic resonance spectra were recorded
on Bruker Avance III instruments operating at 500 MHz (Bruker Corporation, Billerica, MA, USA).
The chemical shifts are given in parts per million (ppm) on the delta scale. The solvent peak was used
as reference values for 1H-NMR (CDCl3 = 7.26 ppm) and for 13C-NMR (CDCl3 = 77.16 ppm).
Data are presented as follows: chemical shift, multiplicity (s= singlet, d= doublet, t= triplet,
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q= quartet, quint= quintet, m= multiplet, b= broad), integration, and coupling constants (J/Hz). High-
resolution mass spectra (HRMS) data were recorded on a Bruker micrOTOF spectrometer equipped
with an orthogonal electrospray interface (ESI). Melting points were measured on Stuart SMP3
apparatus from Cole Parmer (London, UK) and are uncorrected. Analytical thin layer chromatography
(TLC plates from Merck KGaA, Darmstadt, Germany) was carried out on silica gel 60 F254 plates
with visualization by ultraviolet light. Reagents and solvents were purified using standard means.
Tetrahydrofuran (THF) was distilled from sodium metal/benzophenone and stored under an argon
atmosphere. Anhydrous reactions were carried out in flame-dried glassware and under an argon
atmosphere. 2,2′,3,3′,5,5′-Hexaiodo-4,4′-bipyridine (1), 2,2′,3,3′,5,5′-hexachloro-4,4′-bipyridine (2),
3,3′,5,5′-tetrachloro-2,2′-diiodo-4,4′-bipyridine (3), 2,2′,5,5′-tetrachloro-3,3′- diiodo-4,4′-bipyridine
(4), 2,2′,3,3′-tetrachloro-5,5′-diiodo-4,4′-bipyridine (5) and 3,3′,5,5′-tetra- chloro-2,2′-dibromo-4,4′-
bipyridine (12) were prepared according to the literature [48]. All other chemicals were used as
received. CD spectra were recorded on a J-810 instrument from Jasco (JASCO International Co. Ltd.,
Tokyo, Japan) at room temperature using 0.15–0.30 mM samples in ethanol and a 1 mm quartz cell,
with the following conditions: 100 nm/min scanning speed, 1 nm data pitch, 4.0 nm bandwidth, 1 s
response time.
3.1.2. Syntheses of 3,3′,5,5′-Tetrachloro-2,2′-diiodo-4,4′-bipyridine (3) and 3,3′,5,5′-tetrachloro-2-iodo-
4,4′-bipyridine (6)
In a dry Schlenk tube were placed 2,2′-dibromo-tetrahalo-4,4′-bipyridine (800 mg, 1.77 mmol), NaI
(1.06 g, 7.08 mmol), CuI (50 mg, 0.35 mmol), and (rac)-trans-N,N-dimethyl- cyclohexane-1,2-diamine
(64 mg, 0.71 mmol). The Schlenk tube was evacuated and filled with argon before addition of degassed
dioxane (5 mL). The mixture was heated at 120 ◦C for 60 h. After cooling to room temperature, NH4OH
(7 mL) and H2O (8 mL) were added. Then, the product was extracted with dichloromethane (4× 40 mL).
After drying over Na2SO4, filtration, and concentration, the mixture was purified by chromatography
on silica gel (pentane/dichloromethane 7/3) to give bipyridine 3 [48] (white powder, 733 mg, 76%, Rf =
0.27) and bipyridine 6 (white powder, 126 mg, 17%, Rf = 0.15). Mp: 126–127 ◦C; 1H-NMR (500 MHz,
CDCl3) δ 8.67 (s, 2H), 8.46 (s, 1H). 13C-NMR (126 MHz, CDCl3) δ 148.0; 147.8; 140.6; 140.3; 137.3; 131.2;
130.9; 119.5. HRMS (ESI-TOF) [M + H]+ m/z: Calcd. for C10H3Cl4IN2 418.8168, found: 418.8152.
3.1.3. General Procedure for the Synthesis of Bipyridines 7, 8 and 14
In a dry Schlenk tube were placed bipyridine 6 (0.28–0.72 mmol) and tetrakis(triphenylphosphine)
palladium (10 mol%). The Schlenk tube was evacuated and filled with argon before addition of
degassed toluene (2–5 mL). Then a boronic acid solution (1 eq.) in methanol (0.5–1.0 mL) was added
and after 10 min of stirring, at room temperature, a sodium carbonate solution (2 eq.) in distilled water
(0.5–1.0 mL) was added. The mixture was heated at 110 ◦C for 20 h. After cooling to room temperature,
brine (10 mL) was added. Then, the product was extracted with dichloromethane (3 × 15 mL). After
drying over Na2SO4, filtration, and concentration, the products were purified by chromatography on
silica gel.
3,3′,5,5′-Tetrachloro-2-iodo-2′-phenyl-4,4′-bipyridine (7)
Compound 7 was obtained as colorless solid (85 mg, 62%) using the following conditions:
6 (150 mg, 0.28 mmol), tetrakis(triphenylphosphine)palladium (32 mg, 0.028 mmol), phenylboronic
acid (34 mg, 0.28 mmol), sodium carbonate (59 mg, 0.55 mmol). Chromatography on silica gel
(cyclohexane/ethyl acetate 95/5). Mp: 105–106 ◦C; 1H-NMR (500 MHz, CDCl3) δ 8.76 (s, 1H), 8.49 (s,
1H), 7.78–7.71 (m, 2H), 7.53–7.46 (m, 3H). 13C-NMR (126 MHz, CDCl3) δ 156.2, 147.8, 147.5, 141.9, 141.3,
137.3, 137.1, 131.2, 129.6, 129.5, 129.1, 128.7, 128.4, 119.5. HRMS (ESI-TOF) [M + H]+ m/z: Calcd. for
C16H8Cl4N2 495.8481, found: 494.8509.
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3,3′,5,5′-Tetrachloro-2-iodo-2′-(4-pyridyl)-4,4′-bipyridine (8)
Compound 8 was obtained as a viscous wax (49 mg, approx. 75% purity according to 1H-NMR
after chromatography on silica gel with eluent: cyclohexane/ethyl acetate/triethylamine 85/10/5) using
the following conditions: 6 (150 mg, 0.28 mmol), tetrakis(triphenylphosphine)palladium (22 mg,
0.019 mmol), 4-pyridinylboronic acid (35 mg, 0.29 mmol), sodium carbonate (59 mg, 0.55 mmol).
A pure sample (13.3 mg, 10% yield) was obtained after HPLC purification on a Chiralpak IA column
(n-hexane/2-propanol 90:10, 0.8 mL/min). 1H-NMR (500 MHz, CDCl3) δ 8.79 (m, 3H), 8.50 (s, 1H), 7.71
(d, J = 5.0 Hz, 2H). 13C-NMR (126 MHz, CDCl3) δ 153.3, 150.1, 148.0, 147.9, 144.6, 142.4, 140.8, 137.2,
131.1, 130.7, 129.1, 124.0, 119.5. HRMS (ESI-TOF) [M + H]+ m/z: Calcd. for C15H7Cl4IN3 495.8433,
found: 494.8400.
3,3′,5,5′-Tetrachloro-2-iodo-2′-(4-((tert-butyldimethylsilyl)oxy)phenyl)-4,4′-bipyridine (14)
Compound 14 was obtained as viscous oil (199 mg, 44%) using the following conditions:
6 (324 mg, 0.72 mmol), tetrakis(triphenylphosphine)palladium (58 mg, 0.0150 mmol), 4-(tert-butyl-
dimethylsilyloxy)-phenylboronic acid (190 mg, 0.753 mmol), sodium carbonate (152 mg, 1.43 mmol).
Chromatography on silica gel (cyclohexane/ethyl acetate 95/5). 1H-NMR (500 MHz, CDCl3) δ 8.72 (s,
1H), 8.48 (s, 1H), 7.68 (d, J = 8.7 Hz, 2H), 6.94 (d, J = 8.7 Hz, 2H), 1.00 (s, 9H), 0.24 (s, 6H). 13C-NMR
(126 MHz, CDCl3) δ 157.1; 155.8; 147.8; 147.3; 141.9; 141.5; 137.3; 131.3; 131.1; 130.1; 128.5; 128.4; 120.0;
119.5; 25.8; 18.4; −4.2. HRMS (ESI-TOF) [M + H]+ m/z: Calcd. for C22H22Cl4IN2OSi 624.9275, found:
624.9295.
3.1.4. 3,3′,5,5′-Tetrachloro-2-iodo-2′-(4-hydroxyphenyl)-4,4′-bipyridine (9)
To a stirred solution of bipyridine 14 (70 mg, 0.11 mmol) in THF (3 mL), under argon and at
0 ◦C, a TBAF solution (0.016 mL, 1M in THF) was slowly added. After 30 min stirring at 0 ◦C,
the reaction was quenched with NH4Cl and extracted with dichloromethane (3 × 10 mL). After drying
over Na2SO4, filtration, and concentration, the product was purified by chromatography on silica gel
(cyclohexane/ethyl acetate 85/15) to give 9 as a viscous wax (50 mg, 87%). 1H-NMR (500 MHz, CDCl3)
δ 8.72 (s, 1H), 8.48 (s, 1H), 7.69 (d, J = 8.7 Hz, 2H), 6.93 (d, J = 8.7 Hz, 2H), 5.24 (s, 1H). 13C- NMR
(126 MHz, CDCl3) δ 156.9; 155.6; 147.8; 147.3; 142.0; 141.4; 137.3; 131.4; 131.2; 129.6; 128.6; 128.4; 119.5;
115.3. HRMS (ESI-TOF) [M + H]+ m/z: Calcd. for C22H22Cl4IN2OSi 510.8430, found: 510.8449.
3.1.5. Synthesis of 3,3’,5,5’-Tetrachloro-2-iodo-2’-hydroxymethyl-4,4’-bipyridine (10)
Bipyridine 3 (0.458 mmol, 250 mg) was dissolved in toluene (5 mL) and the solution was cooled to
−78 ◦C. n-BuLi (1.2 M, 0.458 mmol, 0.38 mL) was added dropwise and the mixture was stirred at −78 ◦C
for 1 h. DMF (0.916 mmol, 71 µL) was added and stirring was continued at the same temperature for
1 h. NaBH4 (1.374 mmol, 52.2 mg) was added followed by methanol (0.5 mL), the cooling bath was
removed and stirring was maintained for 1 h. The mixture was hydrolysed at 0 ◦C and extracted with
ethyl acetate. After drying over Na2SO4, filtration and evaporation, the residue was purified twice
by chromatography on silica gel (cyclohexane/ethyl acetate 9/1) to give bipyridine 10 as colourless
wax (66 mg, 18%). 1H-NMR (500 MHz, CDCl3) δ 8.67 (s, 1H); 8.48 (s, 1H); 4.85 (s, 2H), 3.98 (bs, 1H).
13C-NMR (126 MHz, CDCl3) δ 155.3; 147.8; 146.2; 141.3; 140.3; 137.3; 131.1; 129.6; 128.0; 119.5; 61.9.
HRMS (ESI-TOF) [M + H]+ m/z: Calcd. for C11H5Cl4IN2O 448.8273, found: 448.8281.
3.1.6. Multimilligram Enantioseparation of 7–10
An Agilent Technologies (Waldbronn, Germany) 1100 Series HPLC system (high-pressure binary
gradient system equipped with a diode-array detector operating at multiple wavelengths (220,
254, 280, 360 nm), a programmable autosampler with a 20 L loop, and a thermostatted column
compartment) was employed for analytical and multimilligram separations. Data acquisition and
analysis were carried out with Agilent Technologies ChemStation Version B.04.03 chromatographic data
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software. The UV absorbance is reported as milliabsorbance units (mAU). Chiralcel OD-H (cellulose
tris-3,5-dimethylphenylcarbamate), and Chiralpak IA (amylose tris-3,5-dimethyl- phenylcarbamate) (5
µm; Chiral Technologies Europe, Illkirch, France) were used as analytical (250 × 4.6 mm) chiral columns.
HPLC-grade n-hexane, 2-propanol, and methanol were purchased and used as received. Analyses
were performed in isocratic mode. Chromatographic separations were performed at 22 ◦C. After
multimilligram enantioseparation, the collected fractions were analyzed under the same conditions
used for separation to determine their enantiomeric excess (ee).
3.2. Biological Details
3.2.1. TTR Expression and Purification
Recombinant WT-hTTR and mutants Y78F-, V30M-hTTR were produced using a pET expression
system (GeneCust, Boynes, France) as essentially described by Dolado and co-workers [77]. All the
hTTR proteins were expressed in Escherichia coli BL21-(DE3) cells harboring the corresponding plasmid.
Expression cultures were grown in LB medium supplemented with 100 µg/mL Ampicillin at 36 ◦C to
an optical density (at 600 nm) of 0.5. Protein expression was induced by addition of 0.4 mM IPTG for 5
h, then bacteria were harvested by centrifugation (5500 g for 20 min), washed with PBS and stored at
−80 ◦C. Bacterial pellet was resuspended in 20 mM Tris-HCl pH 7.5, 1 mM ethylenediaminetetraacetic
acid (EDTA), 100 µM PMSF. After enzymatic lysis with 1 mg/mL lysozyme, cells were treated with
2.5 µg/mL deoxyribonuclease I, 10 mM MgCl2, 50 mM NaCl, centrifuged and the clear supernatant
collected. Proteins were fractionated by ammonium sulfate precipitation between 55 and 85% saturation.
The precipitate was dissolved in 20 mM Tris-HCl pH 7.2, dialyzed against the same buffer and then
fractionated by anion exchange chromatography on a Q-Sepharose column with a 0–0.6 M NaCl gradient
in 20 mM Tris pH 7.2. A final step on Superdex 75 was conducted in 10 mM potassium phosphate
pH 7.6 containing 100 mM KCl. The purity of protein fractions was assessed by standard SDS-PAGE
analysis. Pure proteins equilibrated in buffer phosphate 10 mM pH 7.6, 100 mM KCl, 1 mM EDTA
were stored at −20 ◦C. The extinction coefficients of WT- and V30M-TTR, 7.76 × 104 M−1cm−1 [79], and
Y78F-TTR, 6.958 × 104 M−1cm−1 [42], were used to determine the protein concentration by measuring
the absorbance at 280 nm.
3.2.2. Acid-mediated TTR Fibril Formation Assay
The assay was conducted as described by Klabunde and co-workers [34]. 150 µL of a 0.4 mg/mL
(7.2 µM) stock of WT or mutants hTTR in 10 mM phosphate buffer pH 7.6, containing 100 mM KCl and
1 mM EDTA, were incubated with 1.45 µL of the selected drug (dissolved in DMSO) in an Eppendorf
tube at 36 ◦C. After 30 min, the pH was lowered (up to 4.4 in the case of WT or 5.0 in the case of
mutants) by adding 150 µl of acidic sodium acetate buffer 200 mM (pH 4.2 for WT, 4.8 for Y78F and
V30M), containing 100 mM KCl and 1 mM EDTA. The mixtures were incubated at 36 ◦C for 72 h, after
which the samples were vortexed and turbidity was measured at 400 nm in quartz cuvette. The final
concentration of the protein was 3.6 µM, while drug concentrations was 3.6 or 7.2 µM. Data were
expressed as percentage of fibril formation compared to that recorded in absence of drugs defined
to be 100%. The percentage of fibril formation was determined by observing turbidity increase at
400 nm. Each measurement was run in triplicate. Both (M)-9 and (P)-9 were also tested at different
concentrations ranging from 0 to 15 µM. The assay was conducted as described above using WT-TTR
3.6 µM.
3.3. Computationals
3.3.1. Electrostatic Potential Isosurfaces
Conformational search was performed employing the density functional theory (DFT) method
with the B3LYP functional and the 6-311G* basis set, and the Spartan’ 10 Version 1.1.0 (Wavefunction
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Inc., Irvine, CA, USA) program [80]. Geometry optimization and computation of electrostatic potentials
isosurfaces and related parameters (VS extrema, VS,max and VS,min values, given in kJ/mol) were
performed by using Gaussian 09 (DFT, B3LYP, 6-311G*) (Wallingford, CT, USA) [81]. Search for the
exact location of such EP maxima and minima was made through the Multiwfn code [82] and through
its module enabling quantitative analyses of molecular surfaces (isovalue 0.002) [83].
3.3.2. In Silico Docking Study
The crystal structure complex TTR (chains ABCD)-T4 was released from the RCSB protein databank
(PDB ID: 1ICT) (www.rcsb.org) [2]. The crystallographic T4 ligands were extracted and hydrogen
atoms were added to the TTR structure using ADT module. Computational modelling experiments
were carried out on a HP8100 PC and an EXXACT Tensor Workstation TWS-1686525-AMB with OS
Ubuntu 18.4 or Windows 10, and Centos, respectively. The atomic charges were assigned using the
Gasteiger-Marsili method for the 4,4′-bipyridines and the protein [84]. Binding of the compounds
was analysed using MGLTools 1.5.7rc1 [85] and AutoDock 4.2.6 docking programs [68,69]. The
structures were docked using the Lamarckian genetic algorithm (LGA). In the case of the blind docking
procedure, the LGA was defined through a centred grid, coordinates: x = −7.5, y = −45.5, z = 38.5,
with 126 × 126 × 126 grid points in x, y, z dimensions, respectively, spacing 0.550 Å. For the docking
focused on the T4 binding site, 40 × 40 × 40 grid points in x, y, z dimensions, respectively, spacing
0.375 Å. All 4,4′-bipyridine enantiomers were docked with the pyridyl-pyridyl bond fixed, blocking
rotation. The Lamarckian genetic algorithm (LGA) of up to 100 runs was set to the population size of
150 individuals, maximum number of generations and energy evaluations of 27,000 and 25,000,000,
respectively. From the estimated free energy of ligand binding (E.F.E.B., ∆G), the estimated inhibition
constant (E.I.C., Ki) for each 4,4′-bipyridine was calculated. Ki is calculated by the equation: Ki = exp
[(∆G × 1000)/(R × T)] where ∆G is the docking estimated free energy, R (gas constant) = 1.98719 cal/(K
×mol) and T = 298.15 K. Graphical representation of the poses derived from the docking calculation
was obtained using the software Chimera 1.13.1 [70]. 4,4′-Bipyridines 1–10 were constructed by using
the standard bond lengths and angles from the fragment database of GaussView 5.0 and optimized
with Gaussian 09 (DFT, B3LYP, 6-311G*) [81,86]. The explicit σ-hole (ESH) was used as previously
described [51,64,65], in order to account for the charge anisotropy of the electrostatic potential on top
of the halogen atoms. On this basis, a massless dummy atom connected to I and Cl was introduced
manually, by using distance and charge values as described by Hobza and co-workers [65]. The
parameters used for Cl and I were 1.0, 1.6 Å, and 0.1, 0.3 units of positive charge for the extra point
(ExP), respectively (Supplementary Information, Table S7). The reliability of the docking approach
was further verified by extracting the T4 ligands from the T4 binding pocket of the 1ICT.pdb, 3.00
Å resolution crystal structure, and by considering it as a normal ligand. A massless dummy atom
connected to the iodines of T4 was introduced manually in order to model the σ-hole, as previously
described. After repositioning of T4 into the protein, the new T4 location was in accord to the original
X-ray structure of TTR (Supplementary Information, Figure S3), with only minimal conformational
changes (RMSD 0.57 Å), therefore confirming the reliability of the system.
4. Conclusions
Unexplored as a substructure for the development of TTR stabilizers, the 4,4′-bipyridyl motif
has been proposed and used herein for the development of new potential fibrillogenesis inhibitors.
Among the screened derivatives, the 3,3′,5,5′-tetrachloro-2-iodo-4,4′-bipyridyl core emerged as a
key chiral scaffold, and several derivatives containing a 2′-substituent were thus prepared by
focused/specific synthetic procedures. The enantioseparation of these chiral compounds made
available their enantiomers, which were tested against acid-mediated TTR fibrillogenesis. For each
compound, low or moderate differences were observed between the enantiomer pairs M/P. Among
all enantiomers, (M)-3,3′,5,5′-tetrachloro-2′-(4-hydroxyphenyl)- 2-iodo-4,4′-bipyridine proved to be
able to significantly reduce FF of WT-TTR (16% at 7.2 µM of inhibitor concentration). In silico docking
studies within the T4 pocket were carried out in order to rationalize the binding mode and hypothesize
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a possible molecular mechanism for the observed inhibition activity. Both experimental and theoretical
results evidenced the importance of HB sites located in the distinctive 2′-substituent and the capability
of 2-iodine as XB donor. Despite the fact that some issues such as plasma TTR binding selectivity has still
to be tackled and that the new structures need optimization, the present study revealed the potentiality
of halogenated 4,4′-bipyridines for the development of new TTR amyloidogenesis inhibitors.
Supplementary Materials: The following are available online: Figure S1: VS molecular isosurfaces (0.002 au)
calculated for (P) and (M) enantiomers of 9, T4, and Tafamidis, Figure S2: Blind docking poses of compounds
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